Mohammed Zuber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohammed Zuber has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Lorenzo Villa Zapata
Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens Georgia USA
9 shared publications - Shaimaa Elshafie
Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens Georgia USA
5 shared publications - Chia Jie Tan
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
4 shared publications Shifa Taj
Independent Researcher
4 shared publicationsBh Vidhyashree
Sri Adichunchanagiri College of Pharmacy
3 shared publicationsBp Sathish Kumar
Sri Adichunchanagiri College of Pharmacy
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (10)
Concurrent Antidepressant Use and Metastasis Risk Among Women Receiving Tamoxifen for Breast Cancer: A Real‐World Cohort Study
Objective: Concurrent use of antidepressants, particularly cytochrome P450 2D6 (CYP2D6) inhibitors, may reduce tamoxifen bioactivation and effectiveness. However, the clinical significance of this potential interaction remains inconclusive. This study examined whether concurrent antidepressant use is associated with increased metastasis risk among women receiving tamoxifen for nonmetastatic breast cancer. Methods: We conducted a cohort study using the Merative MarketScan Database. Eligible women with nonmetastatic breast cancer were followed from tamoxifen initiation until metastasis, disenrollment, or study end, whichever occurred first. Patients were classified as concurrent users (tamoxifen with overlapping antidepressant prescriptions) or nonusers (tamoxifen only). Time‐dependent Cox models estimated metastasis risk. Analyses were stratified by concurrent exposure duration and CYP2D6 inhibition degree and adjusted for relevant covariates. Results: Among 14,771 women (mean age: 51 ± 10 years), 4780 (32.4%) used tamoxifen concurrently with an antidepressant, most commonly moderate inhibitors ( n = 1815) and least commonly strong inhibitors ( n = 427). Median overlap duration was 8 months (IQR: 3–20). During follow‐up, 443 patients (3.0%) developed metastasis: 161 of 4780 concurrent users (3.4%) versus 282 of 9991 nonusers (2.8%). Concurrent antidepressant use was not significantly associated with metastasis risk (HR = 0.99; 95% CI: 0.81–1.21). Exposure duration was also not significantly associated with metastasis. Use of mixed‐inhibitor regimens was associated with higher risk in partially adjusted models (HR = 1.39; 95% CI: 1.04–1.87), though full adjustment attenuated the association. Conclusions: Concurrent antidepressant use was not significantly associated with increased metastasis risk among women receiving tamoxifen for nonmetastatic breast cancer. Individualized and coordinated decisions regarding antidepressant selection may help balance cancer control goals with the psychological and symptomatic management needs in this population.
- 30 September 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (10)
Open AccessConcurrent Antidepressant Use and Metastasis Risk Among Women Receiving Tamoxifen for Breast Cancer: A Real‐World Cohort Study
Objective: Concurrent use of antidepressants, particularly cytochrome P450 2D6 (CYP2D6) inhibitors, may reduce tamoxifen bioactivation and effectiveness. However, the clinical significance of this potential interaction remains inconclusive. This study examined whether concurrent antidepressant use is associated with increased metastasis risk among women receiving tamoxifen for nonmetastatic breast cancer. Methods: We conducted a cohort study using the Merative MarketScan Database. Eligible women with nonmetastatic breast cancer were followed from tamoxifen initiation until metastasis, disenrollment, or study end, whichever occurred first. Patients were classified as concurrent users (tamoxifen with overlapping antidepressant prescriptions) or nonusers (tamoxifen only). Time‐dependent Cox models estimated metastasis risk. Analyses were stratified by concurrent exposure duration and CYP2D6 inhibition degree and adjusted for relevant covariates. Results: Among 14,771 women (mean age: 51 ± 10 years), 4780 (32.4%) used tamoxifen concurrently with an antidepressant, most commonly moderate inhibitors ( n = 1815) and least commonly strong inhibitors ( n = 427). Median overlap duration was 8 months (IQR: 3–20). During follow‐up, 443 patients (3.0%) developed metastasis: 161 of 4780 concurrent users (3.4%) versus 282 of 9991 nonusers (2.8%). Concurrent antidepressant use was not significantly associated with metastasis risk (HR = 0.99; 95% CI: 0.81–1.21). Exposure duration was also not significantly associated with metastasis. Use of mixed‐inhibitor regimens was associated with higher risk in partially adjusted models (HR = 1.39; 95% CI: 1.04–1.87), though full adjustment attenuated the association. Conclusions: Concurrent antidepressant use was not significantly associated with increased metastasis risk among women receiving tamoxifen for nonmetastatic breast cancer. Individualized and coordinated decisions regarding antidepressant selection may help balance cancer control goals with the psychological and symptomatic management needs in this population.
- Open Access
- 31 August 2026
- Published by Springer Nature in Infection
- p. 1-10
Immunosuppressive medication exposure and risk of invasive fungal and nontuberculous mycobacterial infections following TNF-α inhibitor initiation: a time-varying analysis
Purpose: Invasive fungal and nontuberculous mycobacterial (NTM) infections are important complications following TNF-α inhibitor initiation, but the contribution of additional immunosuppressive medication exposure remains incompletely defined. We evaluated their incidence and spectrum and associations with time-varying immunosuppressive medication exposure. Methods: We conducted a retrospective cohort study using Merative MarketScan data (2018–2022) among adults initiating TNF-α inhibitors. Invasive fungal and NTM infections were identified using ICD-10-CM codes. Systemic glucocorticoid and non-glucocorticoid immunosuppressant exposures were modeled as time-varying variables. Cox proportional hazards models evaluated associations between immunosuppressive medication exposure and infection risk. Results: Among 62,772 adults, 238 (0.4%) developed an invasive fungal or NTM infection after a median of 14.6 months, corresponding to 146 per 100,000 person-years. Histoplasmosis (26%), NTM infections (22%), and coccidioidomycosis (16%) were most common. In time-varying analyses, glucocorticoid exposure alone (aHR 1.77, 95% CI 1.24–2.52) and non-glucocorticoid immunosuppressant exposure alone (aHR 2.25, 95% CI 1.43–3.52) were associated with higher infection risk compared with periods without either exposure. Combined exposure was not associated with infection risk (aHR 1.31, 95% CI 0.92–1.85). Conclusions: Invasive fungal and NTM infections were uncommon following TNF-α inhibitor initiation. Time-varying glucocorticoid and non-glucocorticoid immunosuppressant exposures were associated with higher infection risk, illustrating the importance of dynamic immunosuppressive medication exposure when assessing infection risk during longitudinal care.
- 31 August 2026
- Published by Springer Nature in Infection
- p. 1-10
Open AccessImmunosuppressive medication exposure and risk of invasive fungal and nontuberculous mycobacterial infections following TNF-α inhibitor initiation: a time-varying analysis
Purpose: Invasive fungal and nontuberculous mycobacterial (NTM) infections are important complications following TNF-α inhibitor initiation, but the contribution of additional immunosuppressive medication exposure remains incompletely defined. We evaluated their incidence and spectrum and associations with time-varying immunosuppressive medication exposure. Methods: We conducted a retrospective cohort study using Merative MarketScan data (2018–2022) among adults initiating TNF-α inhibitors. Invasive fungal and NTM infections were identified using ICD-10-CM codes. Systemic glucocorticoid and non-glucocorticoid immunosuppressant exposures were modeled as time-varying variables. Cox proportional hazards models evaluated associations between immunosuppressive medication exposure and infection risk. Results: Among 62,772 adults, 238 (0.4%) developed an invasive fungal or NTM infection after a median of 14.6 months, corresponding to 146 per 100,000 person-years. Histoplasmosis (26%), NTM infections (22%), and coccidioidomycosis (16%) were most common. In time-varying analyses, glucocorticoid exposure alone (aHR 1.77, 95% CI 1.24–2.52) and non-glucocorticoid immunosuppressant exposure alone (aHR 2.25, 95% CI 1.43–3.52) were associated with higher infection risk compared with periods without either exposure. Combined exposure was not associated with infection risk (aHR 1.31, 95% CI 0.92–1.85). Conclusions: Invasive fungal and NTM infections were uncommon following TNF-α inhibitor initiation. Time-varying glucocorticoid and non-glucocorticoid immunosuppressant exposures were associated with higher infection risk, illustrating the importance of dynamic immunosuppressive medication exposure when assessing infection risk during longitudinal care.
- Open Access
- 1 March 2026
- Published by SAGE Publications in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
- Vol. 63
Health Care-Related Tasks of Informal Dementia Caregivers in the U.S.: A Systematic Review with Narrative Synthesis
Health care-related tasks (e.g., making appointments, talking to providers) performed by informal caregivers caring for older adults with dementia have become increasingly common, yet the evidence on caregiving task profiles remains fragmented and has not been comprehensively synthesized. This is a systematic review with narrative synthesis of the patterns of health care-related tasks and the characteristics of caregivers who performed them. We searched PubMed, Embase, PsychInfo, Web of Science, and CINAHL databases. The identified tasks were grouped into health and medical care, advocacy and care coordination, and surrogate tasks. We also reported caregiver characteristics. We included 12 studies. Only 5 studies reported on racial and ethnic minority caregivers. Medication management was the most common health and medical care task. Only 1 study reported surrogate tasks, and 2 studies reported caregivers performing advocacy and care coordination tasks. This study is particularly timely given the recent implementation of the Centers for Medicare and Medicaid Services (CMS) Guiding an Improved Dementia Experience (GUIDE) Model, which includes caregiver support and education as core components of dementia care delivery. Systematically characterizing the health care-related tasks performed by dementia caregivers can inform the design, targeting, and evaluation of the GUIDE Model.
- 1 March 2026
- Published by SAGE Publications in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
- Vol. 63
Open AccessHealth Care-Related Tasks of Informal Dementia Caregivers in the U.S.: A Systematic Review with Narrative Synthesis
Health care-related tasks (e.g., making appointments, talking to providers) performed by informal caregivers caring for older adults with dementia have become increasingly common, yet the evidence on caregiving task profiles remains fragmented and has not been comprehensively synthesized. This is a systematic review with narrative synthesis of the patterns of health care-related tasks and the characteristics of caregivers who performed them. We searched PubMed, Embase, PsychInfo, Web of Science, and CINAHL databases. The identified tasks were grouped into health and medical care, advocacy and care coordination, and surrogate tasks. We also reported caregiver characteristics. We included 12 studies. Only 5 studies reported on racial and ethnic minority caregivers. Medication management was the most common health and medical care task. Only 1 study reported surrogate tasks, and 2 studies reported caregivers performing advocacy and care coordination tasks. This study is particularly timely given the recent implementation of the Centers for Medicare and Medicaid Services (CMS) Guiding an Improved Dementia Experience (GUIDE) Model, which includes caregiver support and education as core components of dementia care delivery. Systematically characterizing the health care-related tasks performed by dementia caregivers can inform the design, targeting, and evaluation of the GUIDE Model.
- Open Access
- 18 February 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Incidence, Recurrence, Timing, and Economic Impact of Infections After CAR T-Cell Therapy: A Real-World Analysis From MarketScan Database
- 18 February 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Open AccessIncidence, Recurrence, Timing, and Economic Impact of Infections After CAR T-Cell Therapy: A Real-World Analysis From MarketScan Database
- Open Access
- 15 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 1956-1971
Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause discontinuation. To evaluate dermatologic and ISR safety of GLP‐1 RAs through a meta‐analysis of randomised controlled trials (RCTs) and disproportionality analysis of data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS). Materials and Methods: PubMed, Embase and Web of Science were searched through December 2024 to identify RCTs reporting ISR or dermatologic outcomes for GLP‐1 RAs. Random‐effects meta‐analysis synthesised trial evidence. A retrospective disproportionality analysis of FAERS data evaluated all approved GLP‐1 RAs. Lower bound reporting odds ratios (LB ROR), proportional reporting ratios (PRR) and information components (IC) were calculated. Results: The pooled meta‐analysis of 14 RCTs that reported ISRs (4861 patients; 396 ISR events) showed increased ISR risk with GLP‐1 RAs versus comparators (risk ratio 3.55; 95% confidence interval, 2.35–5.36; I 2 = 41.4%). Dermatologic events were infrequent and not significantly elevated. FAERS data analysis revealed potential ISR signals for exenatide and dulaglutide. Exenatide was associated with injection‐site haemorrhage (PRR: 27.6; LB ROR: 29.4; IC 025 : 4.6). Dulaglutide showed disproportionate reporting for injection‐site haemorrhage (PRR: 11.5; LB ROR: 11.5; IC 025 : 3.4). Conclusions: GLP‐1 RAs are consistently linked to higher ISR risk, especially with exenatide and dulaglutide, while generalised dermatologic events are rare. Clinicians should counsel patients about ISR risk to support adherence and optimise outcomes.
- 15 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 1956-1971
Open AccessInjection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause discontinuation. To evaluate dermatologic and ISR safety of GLP‐1 RAs through a meta‐analysis of randomised controlled trials (RCTs) and disproportionality analysis of data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS). Materials and Methods: PubMed, Embase and Web of Science were searched through December 2024 to identify RCTs reporting ISR or dermatologic outcomes for GLP‐1 RAs. Random‐effects meta‐analysis synthesised trial evidence. A retrospective disproportionality analysis of FAERS data evaluated all approved GLP‐1 RAs. Lower bound reporting odds ratios (LB ROR), proportional reporting ratios (PRR) and information components (IC) were calculated. Results: The pooled meta‐analysis of 14 RCTs that reported ISRs (4861 patients; 396 ISR events) showed increased ISR risk with GLP‐1 RAs versus comparators (risk ratio 3.55; 95% confidence interval, 2.35–5.36; I 2 = 41.4%). Dermatologic events were infrequent and not significantly elevated. FAERS data analysis revealed potential ISR signals for exenatide and dulaglutide. Exenatide was associated with injection‐site haemorrhage (PRR: 27.6; LB ROR: 29.4; IC 025 : 4.6). Dulaglutide showed disproportionate reporting for injection‐site haemorrhage (PRR: 11.5; LB ROR: 11.5; IC 025 : 3.4). Conclusions: GLP‐1 RAs are consistently linked to higher ISR risk, especially with exenatide and dulaglutide, while generalised dermatologic events are rare. Clinicians should counsel patients about ISR risk to support adherence and optimise outcomes.
- 18 June 2025
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 25 (10) , 1-8
Risk of musculoskeletal disorders associated with Bruton’s tyrosine kinase inhibitors: a disproportionality analysis of FAERS database and meta-analysis
Randomized controlled trials (RCTs) have reported an increased risk of musculoskeletal disorders with BTK inhibitors (BTKis). We conducted a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) and a meta-analysis of RCTs to further investigate. A retrospective case/non-case study was performed using FAERS reports through Q2 2024. Disproportionality analysis calculated Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Information Component (IC) to identify signals (PRR ≥2, lower bound ROR > 1, IC025 > 0). A meta-analysis calculated risk ratios (RR) for musculoskeletal outcomes. In FAERS, ibrutinib was associated with increased reports of muscle spasms [PRR: 2.2 (χ2 : 521.9), LB ROR: 2.1, IC025 = 1.0]. Acalabrutinib showed higher risks for myalgia [PRR: 2.4, LB ROR: 2.0, IC025 = 0.9] and bone pain [PRR: 2.2, LB ROR: 1.6, IC025 = 0.6]. In the meta-analysis, ibrutinib was associated with higher risks of arthralgia (RR: 1.46, 95% CI 1.21-1.76), muscle spasm (RR: 2.32, 95% CI 1.72-3.12), and back pain (RR: 1.22, 95% CI 0.75-1.96). Findings from FAERS and meta-analysis suggest a stronger association between BTKis, particularly ibrutinib, and musculoskeletal adverse events.
- 18 June 2025
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 25 (10) , 1-8
Risk of musculoskeletal disorders associated with Bruton’s tyrosine kinase inhibitors: a disproportionality analysis of FAERS database and meta-analysis
Randomized controlled trials (RCTs) have reported an increased risk of musculoskeletal disorders with BTK inhibitors (BTKis). We conducted a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) and a meta-analysis of RCTs to further investigate. A retrospective case/non-case study was performed using FAERS reports through Q2 2024. Disproportionality analysis calculated Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Information Component (IC) to identify signals (PRR ≥2, lower bound ROR > 1, IC025 > 0). A meta-analysis calculated risk ratios (RR) for musculoskeletal outcomes. In FAERS, ibrutinib was associated with increased reports of muscle spasms [PRR: 2.2 (χ2 : 521.9), LB ROR: 2.1, IC025 = 1.0]. Acalabrutinib showed higher risks for myalgia [PRR: 2.4, LB ROR: 2.0, IC025 = 0.9] and bone pain [PRR: 2.2, LB ROR: 1.6, IC025 = 0.6]. In the meta-analysis, ibrutinib was associated with higher risks of arthralgia (RR: 1.46, 95% CI 1.21-1.76), muscle spasm (RR: 2.32, 95% CI 1.72-3.12), and back pain (RR: 1.22, 95% CI 0.75-1.96). Findings from FAERS and meta-analysis suggest a stronger association between BTKis, particularly ibrutinib, and musculoskeletal adverse events.
- Open Access
- 9 May 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Socioeconomic Status and Breast Cancer Treatment in the United States: Results From a Systematic Literature Review
Background: In 2024, breast cancer is the second most common cancer globally, affecting 2.3 million women. In the United States (US), 310 720 new female breast cancer cases were estimated in 2024. Existing research has identified substantial disparities in breast cancer treatment and survival based on socioeconomic status (SES). This systematic review examines the association between the key SES indicators income, education, and occupation on breast cancer outcomes among the US breast cancer patients. Methods: An electronic search was conducted using Medline®, Embase®, and Web of Science, from inception to December 2023. Observational studies examining the influence of SES indicators on breast cancer outcomes, including treatment receipt, adherence, and survival, were included. Data were summarized qualitatively due to heterogeneity in SES measures and outcome definitions. Results: Of 2600 studies retrieved from the searches, 23 studies met the inclusion criteria (19 cohort, 4 cross-sectional). Women with lower SES were less likely to receive or experience delay in receiving the recommended treatment than women with higher SES. In addition, women with low household income (<$25,000) were more likely to report discontinuations in therapy as compared to women with an income of $50,000 or more. Education level influenced treatment adherence and timely care, with higher educational attainment linked to improved survival rates. Occupational status impacted treatment continuity, with low-wage jobs and inflexible work schedules contributing to delays and discontinuation of care. Conclusion: SES significantly influences breast cancer care and survival, with lower SES associated with delayed treatment, poorer adherence, and worse outcomes. Healthcare interventions and policies focusing on equitable access to quality care tailored to all women, regardless of their socioeconomic background, may improve breast cancer outcomes for the patients with various demographic characteristics in the US.
- 9 May 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Open AccessSocioeconomic Status and Breast Cancer Treatment in the United States: Results From a Systematic Literature Review
Background: In 2024, breast cancer is the second most common cancer globally, affecting 2.3 million women. In the United States (US), 310 720 new female breast cancer cases were estimated in 2024. Existing research has identified substantial disparities in breast cancer treatment and survival based on socioeconomic status (SES). This systematic review examines the association between the key SES indicators income, education, and occupation on breast cancer outcomes among the US breast cancer patients. Methods: An electronic search was conducted using Medline®, Embase®, and Web of Science, from inception to December 2023. Observational studies examining the influence of SES indicators on breast cancer outcomes, including treatment receipt, adherence, and survival, were included. Data were summarized qualitatively due to heterogeneity in SES measures and outcome definitions. Results: Of 2600 studies retrieved from the searches, 23 studies met the inclusion criteria (19 cohort, 4 cross-sectional). Women with lower SES were less likely to receive or experience delay in receiving the recommended treatment than women with higher SES. In addition, women with low household income (<$25,000) were more likely to report discontinuations in therapy as compared to women with an income of $50,000 or more. Education level influenced treatment adherence and timely care, with higher educational attainment linked to improved survival rates. Occupational status impacted treatment continuity, with low-wage jobs and inflexible work schedules contributing to delays and discontinuation of care. Conclusion: SES significantly influences breast cancer care and survival, with lower SES associated with delayed treatment, poorer adherence, and worse outcomes. Healthcare interventions and policies focusing on equitable access to quality care tailored to all women, regardless of their socioeconomic background, may improve breast cancer outcomes for the patients with various demographic characteristics in the US.
- Open Access
- 30 September 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (18) , e70258
Efficacy and Effectiveness Outcomes of Treatments for Double‐Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review
Background: Bruton's tyrosine kinase inhibitors (BTKi) and the B‐cell lymphoma 2 (BCL2) inhibitor venetoclax have significantly improved outcomes and achieved durable remission in patients with chronic lymphocytic leukemia (CLL). BTKi/venetoclax‐treated patients with exposure to both novel agents (regardless of the reason for discontinuation) are classified as “double‐exposed,” and often have poor prognoses. This study aims to assess the efficacy and effectiveness of treatments in double‐exposed CLL patients.Methods: PubMed, Embase, and Web of Science databases were searched until December 2023.Results: We retrieved 3948 articles for screening and included 13 publications covering nine distinct studies. Three clinical trials reported a median PFS of 16.8 months with pirtobrutinib, 13 months with lisocabtagene maraleucel, and 10.1 months with nemtabrutnib. ORR ranged from 58% with nemtabrutinib and 80% with lisocabtagene maraleucel. In observational studies, PFS ranged from 3 months with chemoimmunotherapy to 12 months with BTKi, and ORR ranged from 31.8% with chemoimmunotherapy to 85.7% with chimeric antigen receptors (CAR) T‐cell therapy.Conclusion: This study highlights the limited clinical data on efficacy outcomes for double‐exposed CLL/SLL patients. Pirtobrutinib, lisocabtagene maraleucel, and a combination of ibrutinib and venetoclax have shown promising effects. However, the scarcity of treatment options and efficacy data for patients who have failed BTKi and venetoclax underscores a significant unmet medical need.
- 30 September 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (18) , e70258
Open AccessEfficacy and Effectiveness Outcomes of Treatments for Double‐Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review
Background: Bruton's tyrosine kinase inhibitors (BTKi) and the B‐cell lymphoma 2 (BCL2) inhibitor venetoclax have significantly improved outcomes and achieved durable remission in patients with chronic lymphocytic leukemia (CLL). BTKi/venetoclax‐treated patients with exposure to both novel agents (regardless of the reason for discontinuation) are classified as “double‐exposed,” and often have poor prognoses. This study aims to assess the efficacy and effectiveness of treatments in double‐exposed CLL patients.Methods: PubMed, Embase, and Web of Science databases were searched until December 2023.Results: We retrieved 3948 articles for screening and included 13 publications covering nine distinct studies. Three clinical trials reported a median PFS of 16.8 months with pirtobrutinib, 13 months with lisocabtagene maraleucel, and 10.1 months with nemtabrutnib. ORR ranged from 58% with nemtabrutinib and 80% with lisocabtagene maraleucel. In observational studies, PFS ranged from 3 months with chemoimmunotherapy to 12 months with BTKi, and ORR ranged from 31.8% with chemoimmunotherapy to 85.7% with chimeric antigen receptors (CAR) T‐cell therapy.Conclusion: This study highlights the limited clinical data on efficacy outcomes for double‐exposed CLL/SLL patients. Pirtobrutinib, lisocabtagene maraleucel, and a combination of ibrutinib and venetoclax have shown promising effects. However, the scarcity of treatment options and efficacy data for patients who have failed BTKi and venetoclax underscores a significant unmet medical need.